At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Double Blind, Placebo Controlled, Parallel Group, Pilot Study of 1:1 and 20:1 Ratio of Formulated GWP42003 : GWP42004 Plus GWP42003 and GWP42004 Alone in the Treatment of Dyslipidaemia in Subjects With Type 2 Diabetes
In Brief
A Phase 2 clinical trial evaluating GWP42003, GWP42004, and 1 other intervention for Dyslipidemias and Diabetes Mellitus, Type 2. Completed, enrolled 62 participants across 5 sites.
Detailed Summary
This 15-19 week study is being conducted by GW Pharma Ltd as a pilot study in order to determine the efficacy and safety of two cannabinoids: GWP42004 and GWP42003 alone, or in combination in patients with Type 2 diabetes. This is the first study to determine whether the study medications have a positive benefit for subjects on their cholesterol levels, body weight, liver fat content and other metabolic parameters compared with a placebo medication.
Study Details
Timeline
Interventions
100 mg capsules, PO, BD, 91 days
5 mg capsules, PO, BD, 91 days
5 mg capsules, PO, BD, 91 days
0 mg capsules, QDS, PO, 91 days